What is STAQ Pharma?
STAQ Pharma operates as a specialized 503B outsourcing facility, bridging the gap between traditional pharmaceutical manufacturing and hospital-level clinical needs. The company utilizes advanced automation to produce sterile and non-sterile compounded medications, with a specific focus on high-precision dosing for both adult and pediatric patient populations. By adhering to rigorous cGMP standards and FDA regulations, STAQ Pharma mitigates the risks associated with manual compounding, ensuring that healthcare providers have reliable access to critical medications during surgical and emergency procedures. Their facility in Denver serves as a hub for innovation in sterile medication production, emphasizing the necessity of quality control in the pharmaceutical lifecycle.
How much funding has STAQ Pharma raised?
STAQ Pharma has raised a total of $43M across 1 funding round:
Series C
$43M
Series C (2022): $43M with participation from Froedtert Health, LCMC Health, UNC Health Care, and University Hospitals
Key Investors in STAQ Pharma
Froedtert Health
A comprehensive health network and Level III Trauma Center that provides a broad range of inpatient and outpatient services, focusing on community health and specialized wellness.
LCMC Health
A non-profit healthcare system based in Louisiana, known for its extensive pediatric and primary care services, including the Children's Hospital of New Orleans.
UNC Health Care
A state-owned, not-for-profit integrated healthcare system based in North Carolina, dedicated to advancing clinical care, research, and medical education.
What's next for STAQ Pharma?
With this major enterprise-level funding, STAQ Pharma is positioned to scale its manufacturing capacity and further integrate its automated systems into the workflows of major health networks. The strategic backing from prominent healthcare systems suggests a collaborative future where STAQ acts as an extension of hospital pharmacy operations, rather than a mere vendor. Future growth will likely focus on expanding the portfolio of prefilled syringe offerings and enhancing the technological backbone of their sterile-to-sterile production lines. As the company matures, the focus will shift toward optimizing distribution logistics to ensure that the most vulnerable patients—particularly in pediatric care—receive consistent, high-quality therapeutic interventions without the threat of supply chain disruption.
See full STAQ Pharma company page
